Spreading the Cell and Gene Word
Keith Thompson joins OVID Health in time for the launch of The Cell and Gene Collective, which aims to boost patient access and awareness of cell and gene therapies
James Strachan | | Quick Read
The development of cell and gene therapies has progressed with incredible pace. Dozens are now available, including three CAR T-cell therapies. Hundreds of clinical trials are underway, investigating treatments for solid tumors and even “cures” for blindness. It’s a hot topic in the pharmaceutical industry, but are doctors and regulators ready? And are patients prepared for this new frontier of medicine?
To help ensure patients who could benefit from advanced medicines do so, specialist communications agency, OVID Health, is set to launch the Cell and Gene Collective in the new year. “The unifying force behind the Collective is patients” said Roudie Shafie, Director at OVID Health and former head of the Association of British Pharmaceutical Industry’s Government Affairs team. “What that looks like in the short to medium term involves raising awareness of cell and gene therapies, particularly among the policy making and healthcare professional community. We also need to overcome any barriers that occur from regulatory approval onward in getting treatments to the patients who can benefit.”
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine